Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms

Xuefei Huang; Jing Yang; Sijin Yang; Shousong Cao; Dalian Qin; Ya Zhou; Xiaoli Li; Yun Ye; Jianming Wu

doi:10.18632/oncotarget.22170

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms

Xuefei Huang, Jing Yang, Sijin Yang, Shousong Cao, Dalian Qin, Ya Zhou, Xiaoli Li, Yun Ye and Jianming Wu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:102705-102720. https://doi.org/10.18632/oncotarget.22170

Metrics: PDF 2098 views | HTML 8014 views | ?

Abstract

Xuefei Huang1,*, Jing Yang2,*, Sijin Yang3,*, Shousong Cao4, Dalian Qin2, Ya Zhou1, Xiaoli Li5, Yun Ye1,6 and Jianming Wu2

1Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China

2Laboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China

3Department of Cardiology and Neurology, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, China

4Laboratory of Cancer Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China

5Department of R&D, Sichuan CREDIT Pharmaceutical Ltd., Luzhou, Sichuan, 646000, China

6Department of Pharmacy, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China

*These authors have contributed equally to this work

Correspondence to:

Jianming Wu, email: [email protected]

Yun Ye, email: [email protected]

Keywords: tandospirone; 5-HT1A receptor; Parkinson's disease; schizophrenia; mechanisms

Received: July 26, 2017 Accepted: September 20, 2017 Published: October 27, 2017

ABSTRACT

5-hydroxytryptamine (5-HT, serotonin) is an important neurotransmitter in the modulation of the cognitive, behavioral and psychological functions in animals and humans. Among the fourteen subtypes of 5-HT receptor, 5-HT1A receptor has been extensively studied. Tandospirone, an azapirone derivative with strong and selective agonist effect on 5-HT1A receptor, has been used for the treatment of anxiety disorders especially generalized anxiety disorder for decades. Recently, tandospirone showed the efficacy in relieving the syndromes of social anxiety disorder and post-traumatic stress disorder as well as in potentiating the effect of antidepressants in the treatment of depression in both preclinical and clinical studies. More impressively, the beneficial effect of tandospirone has been revealed on improvement of motor dysfunction of Parkinson’s disease and cognitive deficits of schizophrenia either in monotherapy or in combination with other drugs. This review discusses the superiority of tandospirone in the treatment of the disorders and associated mechanisms in central nervous system from the literature.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22170

Publication Alerts

Post-Publication Promotion

Reviews:

Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms

Abstract